Vertex Pharmaceuticals VRTX
CEO: Reshma Kewalramani · Biotechnology · 10,400 employees
Compensation Breakdown
Compensation History
| Year | Salary | Bonus | Stock Awards | Options | Non-Equity | Other | Total |
|---|---|---|---|---|---|---|---|
| 2025 | $1.4M | — | $20.0M | $5.5M | $4.1M | $106K | $31.0M |
| 2024 | $1.3M | — | $18.3M | $6.0M | $1.9M | $120K | $27.6M |
| 2023 | $1.3M | — | $9.5M | $4.7M | $5.5M | $39K | $21.0M |
| 2022 | $1.3M | — | $12.3M | $5.8M | $4.7M | $158K | $24.2M |
All compensation data is sourced from SEC DEF 14A proxy filings submitted to EDGAR. The Economic Policy Institute's CEO pay analysis provides additional context on executive compensation trends across industries.
Named Executive Officers
Peer CEO Compensation
Frequently Asked Questions
Reshma Kewalramani, CEO of Vertex Pharmaceuticals (VRTX), earns $31.0M in total compensation. This includes base salary, stock awards, option awards, and other incentives as reported in the company's most recent DEF 14A proxy statement.
Vertex Pharmaceuticals has a Pay-for-Performance Score of C (59/100). The company's 3-year total shareholder return is +20.8%, and the say-on-pay shareholder vote passed with 87.9% approval.
The CEO-to-median-worker pay ratio at Vertex Pharmaceuticals is 370:1. The median worker at Vertex Pharmaceuticals earns $84K per year, while CEO Reshma Kewalramani earns $31.0M in total compensation.
Vertex Pharmaceuticals employs approximately 10,400 people. The company operates in the Biotechnology industry within the Healthcare sector, generating $10.3B in annual revenue.